Starting Dose of Mounjaro (Tirzepatide)
The starting dose of Mounjaro is 2.5 mg per week, not 5 mg per week. 1
Initial Dosing Protocol
The FDA-approved dosing schedule for tirzepatide begins with a lower dose to minimize gastrointestinal adverse effects while establishing therapeutic benefit:
- Start at 2.5 mg subcutaneously once weekly for 4 weeks 1, 2
- After 4 weeks, increase to 5 mg once weekly 1
- Further dose escalation to 10 mg and ultimately 15 mg once weekly occurs at 4-week intervals based on glycemic response and tolerability 1
This gradual titration approach is critical because gastrointestinal adverse events (nausea, vomiting, diarrhea) are dose-dependent and occur in 17-22% of patients, but are typically mild-to-moderate and transient. 3, 4 The 2.5 mg starting dose for 4 weeks allows patients to develop tolerance before advancing to therapeutic doses.
Why Not Start at 5 mg?
Starting directly at 5 mg would bypass the critical tolerance-building phase and significantly increase the risk of treatment discontinuation due to gastrointestinal side effects. 3 Clinical trials consistently used the 2.5 mg starting dose with 4-week escalation intervals, which demonstrated superior tolerability while achieving remarkable efficacy (HbA1c reductions of 1.87-2.59% and weight loss of 6.2-12.9 kg). 4
Dose Escalation Schedule
After the initial 4-week period at 2.5 mg:
- Weeks 5-8: 5 mg once weekly 1
- Weeks 9-12: 10 mg once weekly (if additional glycemic control needed) 1
- Week 13+: 15 mg once weekly (for maximum glycemic control) 1
Each dose increase should occur only after at least 4 weeks at the current dose to assess tolerance and response. 1
Special Considerations
No dosage adjustments are required for patients with renal impairment, including those with eGFR ≥45 mL/min/1.73 m². 1, 5 This represents a significant advantage over some other antidiabetic medications.
Concomitant medication adjustments are essential: reduce insulin doses by approximately 20% and consider discontinuing or reducing sulfonylureas by 50% when initiating tirzepatide to minimize hypoglycemia risk. 1
Common Pitfall to Avoid
Never start tirzepatide at 5 mg weekly in an attempt to reach therapeutic doses faster—this dramatically increases gastrointestinal adverse events and treatment discontinuation rates. 3 The 2.5 mg starting dose for 4 weeks is mandatory per FDA labeling and supported by all clinical trial data. 1, 2, 6